Management of multiple myeloma

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The most recent NCCN Guidelines for Multiple Myeloma include a ranking of the many treatment options for various settings as "preferred," "other," and "useful in certain circumstances." For patients eligible for autologous stem cell transplant (ASCT), the preferred regimen remains bortezomib/lenalidomide/dexamethasone (category 1) or bortezomib/cyclophosphamide/dexamethasone. Upfront ASCT also remains a preferred strategy for patients who are transplant-eligible, despite highly effective newer agents such as induction therapy. Double (tandem) ASCT may benefit patients with high-risk cytogenetics, such as 17p deletion. Lenalidomide maintenance is the standard posttransplant approach and results in improved progression-free and overall survivals. For relapsed disease, a host of new agents have been shown to improve outcomes, mostly in combination with bortezomib or lenalidomide, but their selection depends largely on response and tolerability to prior therapies.

Original languageEnglish (US)
Pages (from-to)624-627
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number5S
DOIs
StatePublished - May 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this